<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00095498</url>
  </required_header>
  <id_info>
    <org_study_id>20040144</org_study_id>
    <nct_id>NCT00095498</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      This study will determine the efficacy, safety, and tolerability of denosumab (AMG 162) in
      the treatment of Rheumatoid Arthritis (RA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Rheumatoid Arthritis Erosion Score Measured From MRI Assessments (RA-MRI ES) at Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>Fifteen sites in each wrist and 10 sites in each hand were assessed by a blinded and independent reader. Each site was scored from 0 to 10 (in accordance with the European League Against Rheumatism [EULAR]-Outcome Measures in Rheumatology Clinical Trials convention), with each unit increment representing 10% incremental loss of the peripheral 1 cm of articular bone. The Erosion Score is a sum of erosion scores from 50 joint sites in both hands/wrists and ranges from 0 (normal, no erosion) to 500 (worst possible erosion).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>TSS is the sum of erosion and joint space narrowing scores obtained from radiographs of the hands and feet, assessed by 2 independent readers. The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280. Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. The TSS ranged from 0 (normal) to 448 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>TSS is the sum of erosion and joint space narrowing scores obtained from radiographs of the hands and feet, assessed by 2 independent readers. The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280. Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. The TSS ranged from 0 (normal) to 448 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Radiographic Erosion Score at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet, obtained from radiographs of the hands and feet and assessed by 2 independent readers. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Radiographic Erosion Score at Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet, obtained from radiographs of the hands and feet and assessed by 2 independent readers. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Radiographic Joint Space Narrowing Score at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet obtained from radiographs of the hands and feet and assessed by 2 independent readers. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score (indicating worst joint space narrowing) of 168.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Radiographic Joint Space Narrowing Score at Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet obtained from radiographs of the hands and feet and assessed by 2 independent readers. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score (indicating worst joint space narrowing) of 168.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 1</measure>
    <time_frame>Baseline, Month 1</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((month 1 value - baseline value) / baseline value ) x 100. Least squares means are based on a repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to month 6 calculated using ((month 6 value - baseline value) / baseline value ) x 100. Least squares means are based on a repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 1</measure>
    <time_frame>Baseline, Month 1</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((Month 1 value - baseline value) / baseline value ) x 100.
Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 6 calculated using ((Month 6 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Hip Bone Mineral Density at Month 1</measure>
    <time_frame>Baseline, Month 1</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((Month 1 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Hip Bone Mineral Density at Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 6 calculated using ((Month 6 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Hip Bone Mineral Density at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Collagen C-Telopeptide (CTX) at Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Percent change from baseline to Month 3 in serum Collagen C-Telopeptide (CTX) Type I calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum CTX at Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>Percent change from baseline to Month 6 in serum Collagen C-Telopeptide (CTX) Type I calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum CTX at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Percent change from Baseline to Month 12 in serum C-Telopeptide (CTX) Type I calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Procollagen 1 N-terminal Peptide (P1NP) at Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Percent change from baseline to Month 3 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in P1NP at Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>Percent change from baseline to Month 6 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in P1NP at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Percent change from baseline to Month 12 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urine Type II Collagen C-telopeptide (C-Tx) /Creatinine at Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Percent change from baseline to Month 3 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>Percent change from baseline to Month 6 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Percent change from baseline to Month 12 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-Denosumab Binding Antibodies</measure>
    <time_frame>Assessed at Baseline and at Months 1, 3, 6 and 12.</time_frame>
    <description>Serum from participants was tested for antibodies to denosumab by immuoassay at months 1, 3, 6 and 12. The number of participants with anti-denosumab antibodies at any assessment is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-Denosumab Binding Antibody and Neutralizing Antibody</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Serum from participants testing positive for anti-denosumab binding antibodies was tested in a cell-based bioassay for neutralizing activity against denosumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Albumin at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory Chemistry Albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Albumin at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory chemistry albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Albumin at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Albumin at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alkaline Phosphatase at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry alkaline phoshatatse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alkaline Phosphatase at Month 3</measure>
    <time_frame>baseline, month 3</time_frame>
    <description>Laboratory chemisrty alkaline phosphatase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alkaline Phosphatase at Month 6</measure>
    <time_frame>baseline, month 6</time_frame>
    <description>Laboratory chemistry alkaline phosphatase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alkaline Phosphatase at Month 12</measure>
    <time_frame>baseine, month 12</time_frame>
    <description>Laboratory chemistry alkaline phosphatase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bicarbonate at Month 1</measure>
    <time_frame>baseline, month 1</time_frame>
    <description>Laboratory chemistry bicarbonate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bicarbonate at Month 3</measure>
    <time_frame>baseline, month 3</time_frame>
    <description>Laboratory chemistry bicarbonate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bicarbonate at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry bicarbonate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bicarbonate at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Laboratory chemistry bicarbonate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Bilirubin at Month 1</measure>
    <time_frame>baseline, month 1</time_frame>
    <description>Laboratory chemistry total bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Bilirubin at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory chemistry total bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Bilirubin at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry total bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Bilirubin at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry total bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Urea Nitrogen at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry blood urea nitrogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Urea Nitrogen at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory chemistry blood urea nitrogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Urea Nitrogen at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry blood urea nitrogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Urea Nitrogen at Month 12</measure>
    <time_frame>baseline, month 12</time_frame>
    <description>Laboratory chemistry blood urea nitrogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Calcium at Month 1</measure>
    <time_frame>baseline. month 1</time_frame>
    <description>Laboratory chemistry calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Calcium at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory chemistry calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Calcium at Month 6</measure>
    <time_frame>baseline, month 6</time_frame>
    <description>Laboratory chemistry calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Calcium at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Calcium (Corrected) at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry albumin-adjusted calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Calcium (Corrected) at Month 3</measure>
    <time_frame>baseline, month 3</time_frame>
    <description>Laboratory chemistry albumin-adjusted calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Calcium (Corrected) at Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>Laboratory chemistry albumin-adjusted calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Calcium (Corrected) at Month 12</measure>
    <time_frame>Baselien, Month 12</time_frame>
    <description>Laboratory chemistry albumin-adjusted calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chloride at Month 1</measure>
    <time_frame>baseline, month 1</time_frame>
    <description>Laboratory chemistry chloride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chloride at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory chemistry chloride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chloride at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry chloride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chloride at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry chloride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Creatinine at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Creatinine at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory chemistry creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Creatinine at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Creatinine at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Gamma-Glutamyl Transferase at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry gamma-glutamyl transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Gamma-Glutamyl Transferase at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory chemistry gamma-glutamyl transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Gamma-Glutamyl Transferase at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry gamma-glutamyl transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Gamma-Glutamyl Transferase at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry gamma-glutamyl transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glucose at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glucose at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory chemistry glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glucose at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glucose at Month 12</measure>
    <time_frame>baseline, month 12</time_frame>
    <description>Laboratory chemistry glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Potassium at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Potassium at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory chemistry potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Potassium at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Potassium at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Magnesium at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry magnesium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Magnesium at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory chemistry magnesium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Magnesium at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry magnesium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Magnesium at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry magnesium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sodium at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sodium at Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Change From Baseline in Sodium at Month 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sodium at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sodium at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Phosphorus at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry phosphorus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Phosphorus at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory chemistry phosphorus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Phosphorus at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry phosphorus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Phosphorus at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Change From Baseline in Phosphorus at Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Protein at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry total protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Protein at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory chemistry total protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Protein at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry total protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Protein at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry total protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aspartate Amino Transferase at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry aspartate amino transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aspartate Amino Transferase at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory chemistry aspartate amino transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aspartate Amino Transferase</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry aspartate amino transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aspartate Amino Transferase at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry aspartate amino transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alanine Amino Transferase at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry alanine amino transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alanine Amino Transferase at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory Chemistry alanine amino transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alanine Amino Transferase at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry alanine amino transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alanine Amino Transferase at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry alanine amino transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Basophils at Month 1</measure>
    <time_frame>baseline, month 1</time_frame>
    <description>Laboratory hematology basophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Basophils at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory hematology basophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Basophils at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology basophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Basophils at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology basophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Eosinophils at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology eosinophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Eosinophils at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory hematology eosinophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Eosinophils at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology eosinophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Eosinophils at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology eosinophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematocrit at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematocrit at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory hematology hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematocrit at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematocrit at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory hematology hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lymphocytes at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology lymphocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lymphocytes at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory hematology lymphocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lymphocytes at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology lymphocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lymphocytes at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology lymphocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Monocytes at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology monocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Monocytes at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory hematology monocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Monocytes at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology monocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Monocytes at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology monocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Neutrophils at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology total neutrophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Neutrophils at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory hematology total neutrophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Neutrophils at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology total neutrophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Neutrophils at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology total neutrophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Platelets at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology platelets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Platelets at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory hematology platelets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Platelets at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology platelets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Platelets at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology platelets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Red Blood Cells at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology red blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Red Blood Cells at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratory hematology red blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Red Blood Cells at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology red blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Red Blood Cells at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology red blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in White Blood Cells at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology white blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in White Blood Cells at Month 3</measure>
    <time_frame>Baseline, month 3</time_frame>
    <description>Laboratpry hematology white blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in White Blood Cells at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology white blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in White Blood Cells at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology white blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Common Terminology Criteria for Adverse Events (CTCAE) Grade Greater or Equal to 3</measure>
    <time_frame>Month 1, month 3, month 6, month 12</time_frame>
    <description>Participants with laboratory toxicity of grade 3 or 4, graded according to the Common Terminology Criteria for Adverse Events, version 3.0, on the following general guideline:
Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death related to AE.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">227</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Denosumab 180 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>denosumab</intervention_name>
    <description>For subcutaneous injection</description>
    <arm_group_label>Denosumab 180 mg</arm_group_label>
    <arm_group_label>Denosumab 60 mg</arm_group_label>
    <other_name>AMG 162</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RA.

          -  All subjects will be required to have been taking a stable dose of methotrexate.

          -  Active RA at screening defined as greater than or equal to 6 swollen joints.

          -  The presence of erosive disease

        Exclusion Criteria:

          -  Received any biologic agent (e.g., Enbrel®, Remicade®, Humira®, Kineret®) or Arava®
             within 8 weeks before randomization; past use of these agents is allowed.

          -  Steroid use greater than 15 mg/day.

          -  Scheduled for surgery or joint replacement in the hands, wrists or feet.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R; Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008 May;58(5):1299-309. doi: 10.1002/art.23417.</citation>
    <PMID>18438830</PMID>
  </reference>
  <reference>
    <citation>Deodhar A, Dore RK, Mandel D, Schechtman J, Shergy W, Trapp R, Ory PA, Peterfy CG, Fuerst T, Wang H, Zhou L, Tsuji W, Newmark R. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2010 Apr;62(4):569-74. doi: 10.1002/acr.20004.</citation>
    <PMID>20391513</PMID>
  </reference>
  <reference>
    <citation>Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, Wang H, Tsuji W, Newmark R; Denosumab RA Study Group. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis. 2010 May;69(5):872-5. doi: 10.1136/ard.2009.112920. Epub 2009 Sep 3.</citation>
    <PMID>19734132</PMID>
  </reference>
  <reference>
    <citation>Sharp JT, Tsuji W, Ory P, Harper-Barek C, Wang H, Newmark R. Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care Res (Hoboken). 2010 Apr;62(4):537-44. doi: 10.1002/acr.20172.</citation>
    <PMID>20391509</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2004</study_first_submitted>
  <study_first_submitted_qc>November 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2004</study_first_posted>
  <results_first_submitted>June 25, 2010</results_first_submitted>
  <results_first_submitted_qc>December 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2014</results_first_posted>
  <disposition_first_submitted>November 23, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 23, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 25, 2009</disposition_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>arthritis</keyword>
  <keyword>joint pain</keyword>
  <keyword>Methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Subject Enrolled: 11-Aug-2004 Last Subject Enrolled: 07-Apr-2005</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Denosumab 180 mg</title>
          <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
        </group>
        <group group_id="P2">
          <title>Denosumab 60 mg</title>
          <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Investigational Product</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligibility determined</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Requirement for alternative therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Denosumab 180 mg</title>
          <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
        </group>
        <group group_id="B2">
          <title>Denosumab 60 mg</title>
          <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="78"/>
            <count group_id="B4" value="227"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="11"/>
                    <measurement group_id="B2" value="57.3" spread="11.4"/>
                    <measurement group_id="B3" value="57" spread="11.1"/>
                    <measurement group_id="B4" value="57.4" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="166"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Rheumatoid Arthritis Erosion Score Measured From MRI Assessments (RA-MRI ES) at Month 6</title>
        <description>Fifteen sites in each wrist and 10 sites in each hand were assessed by a blinded and independent reader. Each site was scored from 0 to 10 (in accordance with the European League Against Rheumatism [EULAR]-Outcome Measures in Rheumatology Clinical Trials convention), with each unit increment representing 10% incremental loss of the peripheral 1 cm of articular bone. The Erosion Score is a sum of erosion scores from 50 joint sites in both hands/wrists and ranges from 0 (normal, no erosion) to 500 (worst possible erosion).</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rheumatoid Arthritis Erosion Score Measured From MRI Assessments (RA-MRI ES) at Month 6</title>
          <description>Fifteen sites in each wrist and 10 sites in each hand were assessed by a blinded and independent reader. Each site was scored from 0 to 10 (in accordance with the European League Against Rheumatism [EULAR]-Outcome Measures in Rheumatology Clinical Trials convention), with each unit increment representing 10% incremental loss of the peripheral 1 cm of articular bone. The Erosion Score is a sum of erosion scores from 50 joint sites in both hands/wrists and ranges from 0 (normal, no erosion) to 500 (worst possible erosion).</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="3.49" lower_limit="-13.00" upper_limit="12.53"/>
                    <measurement group_id="O2" value="0.00" spread="3.43" lower_limit="-17.86" upper_limit="9.00"/>
                    <measurement group_id="O3" value="0.49" spread="5.08" lower_limit="-5.50" upper_limit="37.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.264</p_value>
            <method>van Elteren stratified rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>van Elteren stratified rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 12</title>
        <description>TSS is the sum of erosion and joint space narrowing scores obtained from radiographs of the hands and feet, assessed by 2 independent readers. The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280. Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. The TSS ranged from 0 (normal) to 448 (worst).</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 12</title>
          <description>TSS is the sum of erosion and joint space narrowing scores obtained from radiographs of the hands and feet, assessed by 2 independent readers. The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280. Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. The TSS ranged from 0 (normal) to 448 (worst).</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0" lower_limit="-0.5" upper_limit="1"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.180</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 6</title>
        <description>TSS is the sum of erosion and joint space narrowing scores obtained from radiographs of the hands and feet, assessed by 2 independent readers. The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280. Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. The TSS ranged from 0 (normal) to 448 (worst).</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 6</title>
          <description>TSS is the sum of erosion and joint space narrowing scores obtained from radiographs of the hands and feet, assessed by 2 independent readers. The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280. Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. The TSS ranged from 0 (normal) to 448 (worst).</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.602</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.181</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Radiographic Erosion Score at Month 12</title>
        <description>The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet, obtained from radiographs of the hands and feet and assessed by 2 independent readers. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Radiographic Erosion Score at Month 12</title>
          <description>The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet, obtained from radiographs of the hands and feet and assessed by 2 independent readers. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280.</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Radiographic Erosion Score at Month 6</title>
        <description>The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet, obtained from radiographs of the hands and feet and assessed by 2 independent readers. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Radiographic Erosion Score at Month 6</title>
          <description>The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet, obtained from radiographs of the hands and feet and assessed by 2 independent readers. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280.</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.277</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Radiographic Joint Space Narrowing Score at Month 12</title>
        <description>Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet obtained from radiographs of the hands and feet and assessed by 2 independent readers. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score (indicating worst joint space narrowing) of 168.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Radiographic Joint Space Narrowing Score at Month 12</title>
          <description>Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet obtained from radiographs of the hands and feet and assessed by 2 independent readers. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score (indicating worst joint space narrowing) of 168.</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.382</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.488</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Radiographic Joint Space Narrowing Score at Month 6</title>
        <description>Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet obtained from radiographs of the hands and feet and assessed by 2 independent readers. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score (indicating worst joint space narrowing) of 168.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Radiographic Joint Space Narrowing Score at Month 6</title>
          <description>Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet obtained from radiographs of the hands and feet and assessed by 2 independent readers. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score (indicating worst joint space narrowing) of 168.</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0.97"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.236</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.712</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 1</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((month 1 value - baseline value) / baseline value ) x 100. Least squares means are based on a repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
        <time_frame>Baseline, Month 1</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 1 month.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 1</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((month 1 value - baseline value) / baseline value ) x 100. Least squares means are based on a repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 1 month.</population>
          <units>Percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.29"/>
                    <measurement group_id="O2" value="0.59" spread="0.29"/>
                    <measurement group_id="O3" value="-0.34" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.155</p_value>
            <method>Repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 6</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to month 6 calculated using ((month 6 value - baseline value) / baseline value ) x 100. Least squares means are based on a repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 6</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to month 6 calculated using ((month 6 value - baseline value) / baseline value ) x 100. Least squares means are based on a repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
          <units>Percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" spread="0.38"/>
                    <measurement group_id="O2" value="2.40" spread="0.37"/>
                    <measurement group_id="O3" value="0.73" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>2.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>2.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
          <units>Percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" spread="0.40"/>
                    <measurement group_id="O2" value="3.00" spread="0.39"/>
                    <measurement group_id="O3" value="0.80" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>3.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.18</ci_lower_limit>
            <ci_upper_limit>4.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 1</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((Month 1 value - baseline value) / baseline value ) x 100.
Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
        <time_frame>Baseline, Month 1</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 1 month.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 1</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((Month 1 value - baseline value) / baseline value ) x 100.
Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 1 month.</population>
          <units>Percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.38"/>
                    <measurement group_id="O2" value="-0.15" spread="0.38"/>
                    <measurement group_id="O3" value="-0.16" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.986</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.06</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.141</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 6</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 6 calculated using ((Month 6 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 6</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 6 calculated using ((Month 6 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
          <units>Percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.37"/>
                    <measurement group_id="O2" value="0.89" spread="0.37"/>
                    <measurement group_id="O3" value="-0.06" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.073</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>1.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 12</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 12</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
          <units>Percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.47"/>
                    <measurement group_id="O2" value="1.34" spread="0.47"/>
                    <measurement group_id="O3" value="-0.47" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>3.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>3.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Hip Bone Mineral Density at Month 1</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((Month 1 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
        <time_frame>Baseline, Month 1</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 1 month.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Hip Bone Mineral Density at Month 1</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((Month 1 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 1 month.</population>
          <units>Percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.22"/>
                    <measurement group_id="O2" value="0.00" spread="0.22"/>
                    <measurement group_id="O3" value="-0.02" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.938</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.787</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Hip Bone Mineral Density at Month 6</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 6 calculated using ((Month 6 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Hip Bone Mineral Density at Month 6</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 6 calculated using ((Month 6 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
          <units>Percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.24"/>
                    <measurement group_id="O2" value="0.95" spread="0.24"/>
                    <measurement group_id="O3" value="-0.06" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Hip Bone Mineral Density at Month 12</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Hip Bone Mineral Density at Month 12</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
          <units>Percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.33"/>
                    <measurement group_id="O2" value="1.56" spread="0.33"/>
                    <measurement group_id="O3" value="-0.38" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>2.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>2.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Collagen C-Telopeptide (CTX) at Month 3</title>
        <description>Percent change from baseline to Month 3 in serum Collagen C-Telopeptide (CTX) Type I calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 3 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Collagen C-Telopeptide (CTX) at Month 3</title>
          <description>Percent change from baseline to Month 3 in serum Collagen C-Telopeptide (CTX) Type I calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 3 months.</population>
          <units>Percent change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-78.67" lower_limit="-86.29" upper_limit="-62.86"/>
                    <measurement group_id="O2" value="-80.46" lower_limit="-86.27" upper_limit="-66.84"/>
                    <measurement group_id="O3" value="-11.48" lower_limit="-26.95" upper_limit="15.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum CTX at Month 6</title>
        <description>Percent change from baseline to Month 6 in serum Collagen C-Telopeptide (CTX) Type I calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum CTX at Month 6</title>
          <description>Percent change from baseline to Month 6 in serum Collagen C-Telopeptide (CTX) Type I calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
          <units>Percent change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-62.69" lower_limit="-78.56" upper_limit="-46.23"/>
                    <measurement group_id="O2" value="-50.64" lower_limit="-63.31" upper_limit="-22.37"/>
                    <measurement group_id="O3" value="-12.94" lower_limit="-31.20" upper_limit="23.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum CTX at Month 12</title>
        <description>Percent change from Baseline to Month 12 in serum C-Telopeptide (CTX) Type I calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum CTX at Month 12</title>
          <description>Percent change from Baseline to Month 12 in serum C-Telopeptide (CTX) Type I calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
          <units>Percent change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65.65" lower_limit="-78.62" upper_limit="-48.40"/>
                    <measurement group_id="O2" value="-47.24" lower_limit="-63.60" upper_limit="-27.20"/>
                    <measurement group_id="O3" value="-23.36" lower_limit="-45.43" upper_limit="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Procollagen 1 N-terminal Peptide (P1NP) at Month 3</title>
        <description>Percent change from baseline to Month 3 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 3 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Procollagen 1 N-terminal Peptide (P1NP) at Month 3</title>
          <description>Percent change from baseline to Month 3 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 3 months.</population>
          <units>Percent change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.08" lower_limit="-69.30" upper_limit="-44.40"/>
                    <measurement group_id="O2" value="-57.57" lower_limit="-70.07" upper_limit="-46.07"/>
                    <measurement group_id="O3" value="-12.23" lower_limit="-21.57" upper_limit="-0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in P1NP at Month 6</title>
        <description>Percent change from baseline to Month 6 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in P1NP at Month 6</title>
          <description>Percent change from baseline to Month 6 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
          <units>Percent change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.06" lower_limit="-67.17" upper_limit="-37.13"/>
                    <measurement group_id="O2" value="-51.57" lower_limit="-64.51" upper_limit="-37.35"/>
                    <measurement group_id="O3" value="-22.17" lower_limit="-39.69" upper_limit="-3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in P1NP at Month 12</title>
        <description>Percent change from baseline to Month 12 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in P1NP at Month 12</title>
          <description>Percent change from baseline to Month 12 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
          <units>Percent change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.84" lower_limit="-61.36" upper_limit="-30.09"/>
                    <measurement group_id="O2" value="-41.8" lower_limit="-57.30" upper_limit="-18.89"/>
                    <measurement group_id="O3" value="-17.53" lower_limit="-31.42" upper_limit="-0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urine Type II Collagen C-telopeptide (C-Tx) /Creatinine at Month 3</title>
        <description>Percent change from baseline to Month 3 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 3 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urine Type II Collagen C-telopeptide (C-Tx) /Creatinine at Month 3</title>
          <description>Percent change from baseline to Month 3 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 3 months.</population>
          <units>Percent change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.59" lower_limit="-71.58" upper_limit="4.17"/>
                    <measurement group_id="O2" value="-35.8" lower_limit="-56.80" upper_limit="16.99"/>
                    <measurement group_id="O3" value="2.71" lower_limit="-24.18" upper_limit="31.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 6</title>
        <description>Percent change from baseline to Month 6 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 6</title>
          <description>Percent change from baseline to Month 6 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 6 months.</population>
          <units>Percent change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.17" lower_limit="-32.43" upper_limit="88.27"/>
                    <measurement group_id="O2" value="9.65" lower_limit="-21.79" upper_limit="51.16"/>
                    <measurement group_id="O3" value="4.54" lower_limit="-27.44" upper_limit="56.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.673</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.589</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 12</title>
        <description>Percent change from baseline to Month 12 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 12</title>
          <description>Percent change from baseline to Month 12 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
          <population>All randomized patients who received at least 1 dose of investigational product with a non-missing baseline and at least 1 non-missing postbaseline measurement, and with available data at 12 months.</population>
          <units>Percent change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.92" lower_limit="4.50" upper_limit="111.51"/>
                    <measurement group_id="O2" value="61.92" lower_limit="-15.84" upper_limit="108.60"/>
                    <measurement group_id="O3" value="-3.93" lower_limit="-37.70" upper_limit="126.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.175</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.133</p_value>
            <method>van Elteren Stratified Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-Denosumab Binding Antibodies</title>
        <description>Serum from participants was tested for antibodies to denosumab by immuoassay at months 1, 3, 6 and 12. The number of participants with anti-denosumab antibodies at any assessment is reported.</description>
        <time_frame>Assessed at Baseline and at Months 1, 3, 6 and 12.</time_frame>
        <population>Patients who received at least 1 dose of investigational product and with at least one postbaseline sample taken.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Denosumab Binding Antibodies</title>
          <description>Serum from participants was tested for antibodies to denosumab by immuoassay at months 1, 3, 6 and 12. The number of participants with anti-denosumab antibodies at any assessment is reported.</description>
          <population>Patients who received at least 1 dose of investigational product and with at least one postbaseline sample taken.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-Denosumab Binding Antibody and Neutralizing Antibody</title>
        <description>Serum from participants testing positive for anti-denosumab binding antibodies was tested in a cell-based bioassay for neutralizing activity against denosumab.</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>Patients who were positive for anti-denosumab antibodies</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Denosumab Binding Antibody and Neutralizing Antibody</title>
          <description>Serum from participants testing positive for anti-denosumab binding antibodies was tested in a cell-based bioassay for neutralizing activity against denosumab.</description>
          <population>Patients who were positive for anti-denosumab antibodies</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Albumin at Month 1</title>
        <description>Laboratory Chemistry Albumin</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Albumin at Month 1</title>
          <description>Laboratory Chemistry Albumin</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="2.29"/>
                    <measurement group_id="O2" value="-0.24" spread="2.25"/>
                    <measurement group_id="O3" value="-0.30" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Albumin at Month 3</title>
        <description>Laboratory chemistry albumin</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Albumin at Month 3</title>
          <description>Laboratory chemistry albumin</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="2.18"/>
                    <measurement group_id="O2" value="-0.12" spread="2.28"/>
                    <measurement group_id="O3" value="-0.18" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Albumin at Month 6</title>
        <description>Laboratory chemistry albumin</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Albumin at Month 6</title>
          <description>Laboratory chemistry albumin</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="2.49"/>
                    <measurement group_id="O2" value="-0.90" spread="2.56"/>
                    <measurement group_id="O3" value="-0.77" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Albumin at Month 12</title>
        <description>Laboratory chemistry albumin</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Albumin at Month 12</title>
          <description>Laboratory chemistry albumin</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="2.41"/>
                    <measurement group_id="O2" value="-0.06" spread="2.26"/>
                    <measurement group_id="O3" value="-0.59" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alkaline Phosphatase at Month 1</title>
        <description>Laboratory chemistry alkaline phoshatatse</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alkaline Phosphatase at Month 1</title>
          <description>Laboratory chemistry alkaline phoshatatse</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.87" spread="10.52"/>
                    <measurement group_id="O2" value="-3.66" spread="11.97"/>
                    <measurement group_id="O3" value="1.18" spread="15.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alkaline Phosphatase at Month 3</title>
        <description>Laboratory chemisrty alkaline phosphatase</description>
        <time_frame>baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alkaline Phosphatase at Month 3</title>
          <description>Laboratory chemisrty alkaline phosphatase</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.27" spread="15.91"/>
                    <measurement group_id="O2" value="-12.38" spread="13.09"/>
                    <measurement group_id="O3" value="-2.03" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alkaline Phosphatase at Month 6</title>
        <description>Laboratory chemistry alkaline phosphatase</description>
        <time_frame>baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alkaline Phosphatase at Month 6</title>
          <description>Laboratory chemistry alkaline phosphatase</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.84" spread="31.94"/>
                    <measurement group_id="O2" value="-12.49" spread="12.61"/>
                    <measurement group_id="O3" value="-0.54" spread="18.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alkaline Phosphatase at Month 12</title>
        <description>Laboratory chemistry alkaline phosphatase</description>
        <time_frame>baseine, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alkaline Phosphatase at Month 12</title>
          <description>Laboratory chemistry alkaline phosphatase</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.92" spread="16.74"/>
                    <measurement group_id="O2" value="-11.34" spread="18.18"/>
                    <measurement group_id="O3" value="-4.63" spread="16.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bicarbonate at Month 1</title>
        <description>Laboratory chemistry bicarbonate</description>
        <time_frame>baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bicarbonate at Month 1</title>
          <description>Laboratory chemistry bicarbonate</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="2.31"/>
                    <measurement group_id="O2" value="0.06" spread="3.06"/>
                    <measurement group_id="O3" value="0.54" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bicarbonate at Month 3</title>
        <description>Laboratory chemistry bicarbonate</description>
        <time_frame>baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bicarbonate at Month 3</title>
          <description>Laboratory chemistry bicarbonate</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="2.40"/>
                    <measurement group_id="O2" value="0.39" spread="2.84"/>
                    <measurement group_id="O3" value="-0.67" spread="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bicarbonate at Month 6</title>
        <description>Laboratory chemistry bicarbonate</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bicarbonate at Month 6</title>
          <description>Laboratory chemistry bicarbonate</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="2.29"/>
                    <measurement group_id="O2" value="-0.12" spread="2.61"/>
                    <measurement group_id="O3" value="-0.18" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bicarbonate at Month 12</title>
        <description>Laboratory chemistry bicarbonate</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bicarbonate at Month 12</title>
          <description>Laboratory chemistry bicarbonate</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="2.12"/>
                    <measurement group_id="O2" value="0.58" spread="2.68"/>
                    <measurement group_id="O3" value="0.23" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Bilirubin at Month 1</title>
        <description>Laboratory chemistry total bilirubin</description>
        <time_frame>baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Bilirubin at Month 1</title>
          <description>Laboratory chemistry total bilirubin</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="2.39"/>
                    <measurement group_id="O2" value="-0.23" spread="2.45"/>
                    <measurement group_id="O3" value="0.42" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Bilirubin at Month 3</title>
        <description>Laboratory chemistry total bilirubin</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Bilirubin at Month 3</title>
          <description>Laboratory chemistry total bilirubin</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="2.17"/>
                    <measurement group_id="O2" value="-0.23" spread="2.36"/>
                    <measurement group_id="O3" value="0.44" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Bilirubin at Month 6</title>
        <description>Laboratory chemistry total bilirubin</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Bilirubin at Month 6</title>
          <description>Laboratory chemistry total bilirubin</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="2.58"/>
                    <measurement group_id="O2" value="-0.61" spread="2.49"/>
                    <measurement group_id="O3" value="0.34" spread="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Bilirubin at Month 12</title>
        <description>Laboratory chemistry total bilirubin</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Bilirubin at Month 12</title>
          <description>Laboratory chemistry total bilirubin</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="2.58"/>
                    <measurement group_id="O2" value="-0.35" spread="2.28"/>
                    <measurement group_id="O3" value="0.03" spread="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Urea Nitrogen at Month 1</title>
        <description>Laboratory chemistry blood urea nitrogen</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Urea Nitrogen at Month 1</title>
          <description>Laboratory chemistry blood urea nitrogen</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="1.35"/>
                    <measurement group_id="O2" value="0.15" spread="1.40"/>
                    <measurement group_id="O3" value="-0.01" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Urea Nitrogen at Month 3</title>
        <description>Laboratory chemistry blood urea nitrogen</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Urea Nitrogen at Month 3</title>
          <description>Laboratory chemistry blood urea nitrogen</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="1.35"/>
                    <measurement group_id="O2" value="0.41" spread="1.59"/>
                    <measurement group_id="O3" value="0.06" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Urea Nitrogen at Month 6</title>
        <description>Laboratory chemistry blood urea nitrogen</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Urea Nitrogen at Month 6</title>
          <description>Laboratory chemistry blood urea nitrogen</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="1.44"/>
                    <measurement group_id="O2" value="-0.08" spread="1.41"/>
                    <measurement group_id="O3" value="-0.04" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Urea Nitrogen at Month 12</title>
        <description>Laboratory chemistry blood urea nitrogen</description>
        <time_frame>baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Urea Nitrogen at Month 12</title>
          <description>Laboratory chemistry blood urea nitrogen</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="1.37"/>
                    <measurement group_id="O2" value="0.24" spread="1.46"/>
                    <measurement group_id="O3" value="-0.09" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Calcium at Month 1</title>
        <description>Laboratory chemistry calcium</description>
        <time_frame>baseline. month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Calcium at Month 1</title>
          <description>Laboratory chemistry calcium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.11"/>
                    <measurement group_id="O2" value="-0.05" spread="0.09"/>
                    <measurement group_id="O3" value="0.01" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Calcium at Month 3</title>
        <description>Laboratory chemistry calcium</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Calcium at Month 3</title>
          <description>Laboratory chemistry calcium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.11"/>
                    <measurement group_id="O2" value="-0.02" spread="0.10"/>
                    <measurement group_id="O3" value="0" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Calcium at Month 6</title>
        <description>Laboratory chemistry calcium</description>
        <time_frame>baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Calcium at Month 6</title>
          <description>Laboratory chemistry calcium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.10"/>
                    <measurement group_id="O2" value="-0.03" spread="0.11"/>
                    <measurement group_id="O3" value="-0.01" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Calcium at Month 12</title>
        <description>Laboratory chemistry calcium</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Calcium at Month 12</title>
          <description>Laboratory chemistry calcium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.11"/>
                    <measurement group_id="O2" value="0.01" spread="0.09"/>
                    <measurement group_id="O3" value="0.01" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Calcium (Corrected) at Month 1</title>
        <description>Laboratory chemistry albumin-adjusted calcium</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Calcium (Corrected) at Month 1</title>
          <description>Laboratory chemistry albumin-adjusted calcium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.11"/>
                    <measurement group_id="O2" value="-0.05" spread="0.09"/>
                    <measurement group_id="O3" value="0.01" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Calcium (Corrected) at Month 3</title>
        <description>Laboratory chemistry albumin-adjusted calcium</description>
        <time_frame>baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Calcium (Corrected) at Month 3</title>
          <description>Laboratory chemistry albumin-adjusted calcium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.11"/>
                    <measurement group_id="O2" value="-0.02" spread="0.09"/>
                    <measurement group_id="O3" value="0" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Calcium (Corrected) at Month 6</title>
        <description>Laboratory chemistry albumin-adjusted calcium</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Calcium (Corrected) at Month 6</title>
          <description>Laboratory chemistry albumin-adjusted calcium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.10"/>
                    <measurement group_id="O2" value="-0.02" spread="0.10"/>
                    <measurement group_id="O3" value="-0.01" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Calcium (Corrected) at Month 12</title>
        <description>Laboratory chemistry albumin-adjusted calcium</description>
        <time_frame>Baselien, Month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Calcium (Corrected) at Month 12</title>
          <description>Laboratory chemistry albumin-adjusted calcium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.11"/>
                    <measurement group_id="O2" value="0.01" spread="0.09"/>
                    <measurement group_id="O3" value="0" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chloride at Month 1</title>
        <description>Laboratory chemistry chloride</description>
        <time_frame>baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chloride at Month 1</title>
          <description>Laboratory chemistry chloride</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="2.36"/>
                    <measurement group_id="O2" value="0.58" spread="2.66"/>
                    <measurement group_id="O3" value="0.01" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chloride at Month 3</title>
        <description>Laboratory chemistry chloride</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chloride at Month 3</title>
          <description>Laboratory chemistry chloride</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="2.67"/>
                    <measurement group_id="O2" value="0.38" spread="2.35"/>
                    <measurement group_id="O3" value="0.78" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chloride at Month 6</title>
        <description>Laboratory chemistry chloride</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chloride at Month 6</title>
          <description>Laboratory chemistry chloride</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="2.85"/>
                    <measurement group_id="O2" value="0.48" spread="2.19"/>
                    <measurement group_id="O3" value="0" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chloride at Month 12</title>
        <description>Laboratory chemistry chloride</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chloride at Month 12</title>
          <description>Laboratory chemistry chloride</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="2.45"/>
                    <measurement group_id="O2" value="-0.21" spread="2.58"/>
                    <measurement group_id="O3" value="-0.08" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Creatinine at Month 1</title>
        <description>Laboratory chemistry creatinine</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Creatinine at Month 1</title>
          <description>Laboratory chemistry creatinine</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="9.89"/>
                    <measurement group_id="O2" value="0.38" spread="8.63"/>
                    <measurement group_id="O3" value="1.47" spread="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Creatinine at Month 3</title>
        <description>Laboratory chemistry creatinine</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Creatinine at Month 3</title>
          <description>Laboratory chemistry creatinine</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="11.11"/>
                    <measurement group_id="O2" value="3.20" spread="8.30"/>
                    <measurement group_id="O3" value="3.81" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Creatinine at Month 6</title>
        <description>Laboratory chemistry creatinine</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Creatinine at Month 6</title>
          <description>Laboratory chemistry creatinine</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="10.97"/>
                    <measurement group_id="O2" value="3.84" spread="9.88"/>
                    <measurement group_id="O3" value="3.54" spread="11.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Creatinine at Month 12</title>
        <description>Laboratory chemistry creatinine</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Creatinine at Month 12</title>
          <description>Laboratory chemistry creatinine</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.44" spread="10.09"/>
                    <measurement group_id="O2" value="4.42" spread="9.59"/>
                    <measurement group_id="O3" value="3.73" spread="7.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Gamma-Glutamyl Transferase at Month 1</title>
        <description>Laboratory chemistry gamma-glutamyl transferase</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Gamma-Glutamyl Transferase at Month 1</title>
          <description>Laboratory chemistry gamma-glutamyl transferase</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="8.13"/>
                    <measurement group_id="O2" value="-1.25" spread="9.67"/>
                    <measurement group_id="O3" value="0.26" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Gamma-Glutamyl Transferase at Month 3</title>
        <description>Laboratory chemistry gamma-glutamyl transferase</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Gamma-Glutamyl Transferase at Month 3</title>
          <description>Laboratory chemistry gamma-glutamyl transferase</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="10.94"/>
                    <measurement group_id="O2" value="0.04" spread="9.90"/>
                    <measurement group_id="O3" value="1.51" spread="15.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Gamma-Glutamyl Transferase at Month 6</title>
        <description>Laboratory chemistry gamma-glutamyl transferase</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Gamma-Glutamyl Transferase at Month 6</title>
          <description>Laboratory chemistry gamma-glutamyl transferase</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.37" spread="36.42"/>
                    <measurement group_id="O2" value="0.28" spread="12.70"/>
                    <measurement group_id="O3" value="5.67" spread="37.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Gamma-Glutamyl Transferase at Month 12</title>
        <description>Laboratory chemistry gamma-glutamyl transferase</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Gamma-Glutamyl Transferase at Month 12</title>
          <description>Laboratory chemistry gamma-glutamyl transferase</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="10.94"/>
                    <measurement group_id="O2" value="1.08" spread="16.09"/>
                    <measurement group_id="O3" value="-1.38" spread="14.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glucose at Month 1</title>
        <description>Laboratory chemistry glucose</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glucose at Month 1</title>
          <description>Laboratory chemistry glucose</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.76"/>
                    <measurement group_id="O2" value="0.20" spread="0.65"/>
                    <measurement group_id="O3" value="0.05" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glucose at Month 3</title>
        <description>Laboratory chemistry glucose</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glucose at Month 3</title>
          <description>Laboratory chemistry glucose</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.87"/>
                    <measurement group_id="O2" value="0.20" spread="0.63"/>
                    <measurement group_id="O3" value="0.04" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glucose at Month 6</title>
        <description>Laboratory chemistry glucose</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glucose at Month 6</title>
          <description>Laboratory chemistry glucose</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.85"/>
                    <measurement group_id="O2" value="0.20" spread="0.65"/>
                    <measurement group_id="O3" value="-0.05" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glucose at Month 12</title>
        <description>Laboratory chemistry glucose</description>
        <time_frame>baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glucose at Month 12</title>
          <description>Laboratory chemistry glucose</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.66"/>
                    <measurement group_id="O2" value="0.22" spread="0.96"/>
                    <measurement group_id="O3" value="0.19" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Potassium at Month 1</title>
        <description>Laboratory chemistry potassium</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Potassium at Month 1</title>
          <description>Laboratory chemistry potassium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.38"/>
                    <measurement group_id="O2" value="0.06" spread="0.36"/>
                    <measurement group_id="O3" value="0.04" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Potassium at Month 3</title>
        <description>Laboratory chemistry potassium</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Potassium at Month 3</title>
          <description>Laboratory chemistry potassium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.39"/>
                    <measurement group_id="O2" value="0.06" spread="0.40"/>
                    <measurement group_id="O3" value="0.04" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Potassium at Month 6</title>
        <description>Laboratory chemistry potassium</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Potassium at Month 6</title>
          <description>Laboratory chemistry potassium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.44"/>
                    <measurement group_id="O2" value="-0.01" spread="0.36"/>
                    <measurement group_id="O3" value="0" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Potassium at Month 12</title>
        <description>Laboratory chemistry potassium</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Potassium at Month 12</title>
          <description>Laboratory chemistry potassium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.44"/>
                    <measurement group_id="O2" value="-0.08" spread="0.35"/>
                    <measurement group_id="O3" value="-0.04" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Magnesium at Month 1</title>
        <description>Laboratory chemistry magnesium</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Magnesium at Month 1</title>
          <description>Laboratory chemistry magnesium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.06"/>
                    <measurement group_id="O2" value="0.02" spread="0.06"/>
                    <measurement group_id="O3" value="0.01" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Magnesium at Month 3</title>
        <description>Laboratory chemistry magnesium</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Magnesium at Month 3</title>
          <description>Laboratory chemistry magnesium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.06"/>
                    <measurement group_id="O2" value="0.02" spread="0.06"/>
                    <measurement group_id="O3" value="0" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Magnesium at Month 6</title>
        <description>Laboratory chemistry magnesium</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Magnesium at Month 6</title>
          <description>Laboratory chemistry magnesium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.06"/>
                    <measurement group_id="O2" value="0.01" spread="0.06"/>
                    <measurement group_id="O3" value="0.01" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Magnesium at Month 12</title>
        <description>Laboratory chemistry magnesium</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Magnesium at Month 12</title>
          <description>Laboratory chemistry magnesium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.06"/>
                    <measurement group_id="O2" value="-0.01" spread="0.07"/>
                    <measurement group_id="O3" value="-0.01" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sodium at Month 1</title>
        <description>Laboratory chemistry sodium</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sodium at Month 1</title>
          <description>Laboratory chemistry sodium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="1.93"/>
                    <measurement group_id="O2" value="-0.06" spread="2.62"/>
                    <measurement group_id="O3" value="0.33" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sodium at Month 3</title>
        <description>Change From Baseline in Sodium at Month 3</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sodium at Month 3</title>
          <description>Change From Baseline in Sodium at Month 3</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="2.13"/>
                    <measurement group_id="O2" value="-0.16" spread="2.29"/>
                    <measurement group_id="O3" value="0.39" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sodium at Month 6</title>
        <description>Laboratory chemistry sodium</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sodium at Month 6</title>
          <description>Laboratory chemistry sodium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="1.98"/>
                    <measurement group_id="O2" value="-0.06" spread="1.75"/>
                    <measurement group_id="O3" value="0.03" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sodium at Month 12</title>
        <description>Laboratory chemistry sodium</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sodium at Month 12</title>
          <description>Laboratory chemistry sodium</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="2.02"/>
                    <measurement group_id="O2" value="-0.27" spread="2.75"/>
                    <measurement group_id="O3" value="0.33" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Phosphorus at Month 1</title>
        <description>Laboratory chemistry phosphorus</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Phosphorus at Month 1</title>
          <description>Laboratory chemistry phosphorus</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.16"/>
                    <measurement group_id="O2" value="-0.06" spread="0.19"/>
                    <measurement group_id="O3" value="0.02" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Phosphorus at Month 3</title>
        <description>Laboratory chemistry phosphorus</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Phosphorus at Month 3</title>
          <description>Laboratory chemistry phosphorus</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.16"/>
                    <measurement group_id="O2" value="-0.03" spread="0.18"/>
                    <measurement group_id="O3" value="0.01" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Phosphorus at Month 6</title>
        <description>Laboratory chemistry phosphorus</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Phosphorus at Month 6</title>
          <description>Laboratory chemistry phosphorus</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.17"/>
                    <measurement group_id="O2" value="-0.01" spread="0.18"/>
                    <measurement group_id="O3" value="0.03" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Phosphorus at Month 12</title>
        <description>Change From Baseline in Phosphorus at Month 12</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Phosphorus at Month 12</title>
          <description>Change From Baseline in Phosphorus at Month 12</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.17"/>
                    <measurement group_id="O2" value="0" spread="0.17"/>
                    <measurement group_id="O3" value="0" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Protein at Month 1</title>
        <description>Laboratory chemistry total protein</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Protein at Month 1</title>
          <description>Laboratory chemistry total protein</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="3.56"/>
                    <measurement group_id="O2" value="-0.40" spread="3.22"/>
                    <measurement group_id="O3" value="0.21" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Protein at Month 3</title>
        <description>Laboratory chemistry total protein</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Protein at Month 3</title>
          <description>Laboratory chemistry total protein</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="3.35"/>
                    <measurement group_id="O2" value="0.07" spread="3.42"/>
                    <measurement group_id="O3" value="-0.20" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Protein at Month 6</title>
        <description>Laboratory chemistry total protein</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Protein at Month 6</title>
          <description>Laboratory chemistry total protein</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="4.13"/>
                    <measurement group_id="O2" value="-0.62" spread="3.40"/>
                    <measurement group_id="O3" value="-0.57" spread="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Protein at Month 12</title>
        <description>Laboratory chemistry total protein</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Protein at Month 12</title>
          <description>Laboratory chemistry total protein</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="3.76"/>
                    <measurement group_id="O2" value="-0.91" spread="3.55"/>
                    <measurement group_id="O3" value="-0.98" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aspartate Amino Transferase at Month 1</title>
        <description>Laboratory chemistry aspartate amino transferase</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aspartate Amino Transferase at Month 1</title>
          <description>Laboratory chemistry aspartate amino transferase</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="5.84"/>
                    <measurement group_id="O2" value="-0.26" spread="8.14"/>
                    <measurement group_id="O3" value="0.90" spread="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aspartate Amino Transferase at Month 3</title>
        <description>Laboratory chemistry aspartate amino transferase</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aspartate Amino Transferase at Month 3</title>
          <description>Laboratory chemistry aspartate amino transferase</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="5.77"/>
                    <measurement group_id="O2" value="0.40" spread="8.78"/>
                    <measurement group_id="O3" value="2.69" spread="9.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aspartate Amino Transferase</title>
        <description>Laboratory chemistry aspartate amino transferase</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aspartate Amino Transferase</title>
          <description>Laboratory chemistry aspartate amino transferase</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.85" spread="15.66"/>
                    <measurement group_id="O2" value="0.87" spread="7.58"/>
                    <measurement group_id="O3" value="3.24" spread="15.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aspartate Amino Transferase at Month 12</title>
        <description>Laboratory chemistry aspartate amino transferase</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aspartate Amino Transferase at Month 12</title>
          <description>Laboratory chemistry aspartate amino transferase</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="18.62"/>
                    <measurement group_id="O2" value="3.75" spread="18.11"/>
                    <measurement group_id="O3" value="2.24" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alanine Amino Transferase at Month 1</title>
        <description>Laboratory chemistry alanine amino transferase</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alanine Amino Transferase at Month 1</title>
          <description>Laboratory chemistry alanine amino transferase</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.84" spread="8.61"/>
                    <measurement group_id="O2" value="-1.03" spread="12.37"/>
                    <measurement group_id="O3" value="1.20" spread="15.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alanine Amino Transferase at Month 3</title>
        <description>Laboratory Chemistry alanine amino transferase</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alanine Amino Transferase at Month 3</title>
          <description>Laboratory Chemistry alanine amino transferase</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="8.85"/>
                    <measurement group_id="O2" value="-2.10" spread="14.34"/>
                    <measurement group_id="O3" value="1.54" spread="13.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alanine Amino Transferase at Month 6</title>
        <description>Laboratory chemistry alanine amino transferase</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alanine Amino Transferase at Month 6</title>
          <description>Laboratory chemistry alanine amino transferase</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="15.83"/>
                    <measurement group_id="O2" value="-1.76" spread="14.12"/>
                    <measurement group_id="O3" value="5.44" spread="51.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alanine Amino Transferase at Month 12</title>
        <description>Laboratory chemistry alanine amino transferase</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alanine Amino Transferase at Month 12</title>
          <description>Laboratory chemistry alanine amino transferase</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.86" spread="24.46"/>
                    <measurement group_id="O2" value="1.66" spread="14.30"/>
                    <measurement group_id="O3" value="1.82" spread="14.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Basophils at Month 1</title>
        <description>Laboratory hematology basophils</description>
        <time_frame>baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Basophils at Month 1</title>
          <description>Laboratory hematology basophils</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>*10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.07"/>
                    <measurement group_id="O2" value="0" spread="0.07"/>
                    <measurement group_id="O3" value="-0.01" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Basophils at Month 3</title>
        <description>Laboratory hematology basophils</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Basophils at Month 3</title>
          <description>Laboratory hematology basophils</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.06"/>
                    <measurement group_id="O2" value="-0.01" spread="0.07"/>
                    <measurement group_id="O3" value="-0.01" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Basophils at Month 6</title>
        <description>Laboratory hematology basophils</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Basophils at Month 6</title>
          <description>Laboratory hematology basophils</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.06"/>
                    <measurement group_id="O2" value="0" spread="0.07"/>
                    <measurement group_id="O3" value="0" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Basophils at Month 12</title>
        <description>Laboratory hematology basophils</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Basophils at Month 12</title>
          <description>Laboratory hematology basophils</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.09"/>
                    <measurement group_id="O2" value="0" spread="0.09"/>
                    <measurement group_id="O3" value="0.03" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Eosinophils at Month 1</title>
        <description>Laboratory hematology eosinophils</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Eosinophils at Month 1</title>
          <description>Laboratory hematology eosinophils</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.09"/>
                    <measurement group_id="O2" value="-0.01" spread="0.09"/>
                    <measurement group_id="O3" value="0.01" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Eosinophils at Month 3</title>
        <description>Laboratory hematology eosinophils</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Eosinophils at Month 3</title>
          <description>Laboratory hematology eosinophils</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.10"/>
                    <measurement group_id="O2" value="0" spread="0.10"/>
                    <measurement group_id="O3" value="-0.01" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Eosinophils at Month 6</title>
        <description>Laboratory hematology eosinophils</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Eosinophils at Month 6</title>
          <description>Laboratory hematology eosinophils</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.09"/>
                    <measurement group_id="O2" value="0" spread="0.13"/>
                    <measurement group_id="O3" value="0" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Eosinophils at Month 12</title>
        <description>Laboratory hematology eosinophils</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Eosinophils at Month 12</title>
          <description>Laboratory hematology eosinophils</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.16"/>
                    <measurement group_id="O2" value="0.02" spread="0.12"/>
                    <measurement group_id="O3" value="0.01" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematocrit at Month 1</title>
        <description>Laboratory hematology hematocrit</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematocrit at Month 1</title>
          <description>Laboratory hematology hematocrit</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.02"/>
                    <measurement group_id="O2" value="0" spread="0.02"/>
                    <measurement group_id="O3" value="0" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematocrit at Month 3</title>
        <description>Laboratory hematology hematocrit</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematocrit at Month 3</title>
          <description>Laboratory hematology hematocrit</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.02"/>
                    <measurement group_id="O2" value="0" spread="0.03"/>
                    <measurement group_id="O3" value="0" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematocrit at Month 6</title>
        <description>Laboratory hematology hematocrit</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematocrit at Month 6</title>
          <description>Laboratory hematology hematocrit</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.02"/>
                    <measurement group_id="O2" value="0" spread="0.03"/>
                    <measurement group_id="O3" value="0" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematocrit at Month 12</title>
        <description>Laboratory hematology hematocrit</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematocrit at Month 12</title>
          <description>Laboratory hematology hematocrit</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.02"/>
                    <measurement group_id="O2" value="0" spread="0.03"/>
                    <measurement group_id="O3" value="-0.01" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin at Month 1</title>
        <description>Laboratory hematology hemoglobin</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin at Month 1</title>
          <description>Laboratory hematology hemoglobin</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="6.73"/>
                    <measurement group_id="O2" value="-1.48" spread="6.39"/>
                    <measurement group_id="O3" value="-0.69" spread="6.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin at Month 3</title>
        <description>Laboratory hematology hemoglobin</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin at Month 3</title>
          <description>Laboratory hematology hemoglobin</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="7.02"/>
                    <measurement group_id="O2" value="-1.02" spread="8.36"/>
                    <measurement group_id="O3" value="-1.10" spread="6.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin at Month 6</title>
        <description>Laboratory hematology hemoglobin</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin at Month 6</title>
          <description>Laboratory hematology hemoglobin</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="7.80"/>
                    <measurement group_id="O2" value="-1.69" spread="8.82"/>
                    <measurement group_id="O3" value="-0.69" spread="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin at Month 12</title>
        <description>Laboratory hematology hemoglobin</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin at Month 12</title>
          <description>Laboratory hematology hemoglobin</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="9.26"/>
                    <measurement group_id="O2" value="0.02" spread="11.66"/>
                    <measurement group_id="O3" value="-0.46" spread="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lymphocytes at Month 1</title>
        <description>Laboratory hematology lymphocytes</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lymphocytes at Month 1</title>
          <description>Laboratory hematology lymphocytes</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.41"/>
                    <measurement group_id="O2" value="0.10" spread="0.40"/>
                    <measurement group_id="O3" value="0" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lymphocytes at Month 3</title>
        <description>Laboratory hematology lymphocytes</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lymphocytes at Month 3</title>
          <description>Laboratory hematology lymphocytes</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.38"/>
                    <measurement group_id="O2" value="0.14" spread="0.48"/>
                    <measurement group_id="O3" value="0.08" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lymphocytes at Month 6</title>
        <description>Laboratory hematology lymphocytes</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lymphocytes at Month 6</title>
          <description>Laboratory hematology lymphocytes</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.41"/>
                    <measurement group_id="O2" value="0.05" spread="0.35"/>
                    <measurement group_id="O3" value="0.03" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lymphocytes at Month 12</title>
        <description>Laboratory hematology lymphocytes</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lymphocytes at Month 12</title>
          <description>Laboratory hematology lymphocytes</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.49"/>
                    <measurement group_id="O2" value="0.04" spread="0.50"/>
                    <measurement group_id="O3" value="-0.02" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Monocytes at Month 1</title>
        <description>Laboratory hematology monocytes</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monocytes at Month 1</title>
          <description>Laboratory hematology monocytes</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.13"/>
                    <measurement group_id="O2" value="-0.01" spread="0.10"/>
                    <measurement group_id="O3" value="0.01" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Monocytes at Month 3</title>
        <description>Laboratory hematology monocytes</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monocytes at Month 3</title>
          <description>Laboratory hematology monocytes</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.11"/>
                    <measurement group_id="O2" value="0.01" spread="0.11"/>
                    <measurement group_id="O3" value="0.02" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Monocytes at Month 6</title>
        <description>Laboratory hematology monocytes</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monocytes at Month 6</title>
          <description>Laboratory hematology monocytes</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.17"/>
                    <measurement group_id="O2" value="0.04" spread="0.12"/>
                    <measurement group_id="O3" value="0.04" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Monocytes at Month 12</title>
        <description>Laboratory hematology monocytes</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monocytes at Month 12</title>
          <description>Laboratory hematology monocytes</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.15"/>
                    <measurement group_id="O2" value="0" spread="0.11"/>
                    <measurement group_id="O3" value="0.02" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Neutrophils at Month 1</title>
        <description>Laboratory hematology total neutrophils</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Neutrophils at Month 1</title>
          <description>Laboratory hematology total neutrophils</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="1.97"/>
                    <measurement group_id="O2" value="0.18" spread="1.99"/>
                    <measurement group_id="O3" value="-0.13" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Neutrophils at Month 3</title>
        <description>Laboratory hematology total neutrophils</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Neutrophils at Month 3</title>
          <description>Laboratory hematology total neutrophils</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="1.92"/>
                    <measurement group_id="O2" value="0.26" spread="1.64"/>
                    <measurement group_id="O3" value="-0.11" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Neutrophils at Month 6</title>
        <description>Laboratory hematology total neutrophils</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Neutrophils at Month 6</title>
          <description>Laboratory hematology total neutrophils</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="1.67"/>
                    <measurement group_id="O2" value="-0.05" spread="1.66"/>
                    <measurement group_id="O3" value="0.27" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Neutrophils at Month 12</title>
        <description>Laboratory hematology total neutrophils</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Neutrophils at Month 12</title>
          <description>Laboratory hematology total neutrophils</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="2.37"/>
                    <measurement group_id="O2" value="0.04" spread="1.79"/>
                    <measurement group_id="O3" value="0.10" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Platelets at Month 1</title>
        <description>Laboratory hematology platelets</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelets at Month 1</title>
          <description>Laboratory hematology platelets</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="44.53"/>
                    <measurement group_id="O2" value="10.36" spread="49.34"/>
                    <measurement group_id="O3" value="2.96" spread="44.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Platelets at Month 3</title>
        <description>Laboratory hematology platelets</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelets at Month 3</title>
          <description>Laboratory hematology platelets</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.82" spread="48.86"/>
                    <measurement group_id="O2" value="6.86" spread="50.18"/>
                    <measurement group_id="O3" value="-1.97" spread="45.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Platelets at Month 6</title>
        <description>Laboratory hematology platelets</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelets at Month 6</title>
          <description>Laboratory hematology platelets</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="54.95"/>
                    <measurement group_id="O2" value="1.00" spread="45.64"/>
                    <measurement group_id="O3" value="1.57" spread="53.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Platelets at Month 12</title>
        <description>Laboratory hematology platelets</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelets at Month 12</title>
          <description>Laboratory hematology platelets</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32" spread="51.66"/>
                    <measurement group_id="O2" value="-4.26" spread="51.12"/>
                    <measurement group_id="O3" value="1.07" spread="58.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Red Blood Cells at Month 1</title>
        <description>Laboratory hematology red blood cells</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Red Blood Cells at Month 1</title>
          <description>Laboratory hematology red blood cells</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.21"/>
                    <measurement group_id="O2" value="-0.01" spread="0.20"/>
                    <measurement group_id="O3" value="-0.01" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Red Blood Cells at Month 3</title>
        <description>Laboratory hematology red blood cells</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Red Blood Cells at Month 3</title>
          <description>Laboratory hematology red blood cells</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.23"/>
                    <measurement group_id="O2" value="0.02" spread="0.28"/>
                    <measurement group_id="O3" value="0" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Red Blood Cells at Month 6</title>
        <description>Laboratory hematology red blood cells</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Red Blood Cells at Month 6</title>
          <description>Laboratory hematology red blood cells</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.24"/>
                    <measurement group_id="O2" value="-0.04" spread="0.26"/>
                    <measurement group_id="O3" value="0.01" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Red Blood Cells at Month 12</title>
        <description>Laboratory hematology red blood cells</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Red Blood Cells at Month 12</title>
          <description>Laboratory hematology red blood cells</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.27"/>
                    <measurement group_id="O2" value="-0.06" spread="0.30"/>
                    <measurement group_id="O3" value="-0.03" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in White Blood Cells at Month 1</title>
        <description>Laboratory hematology white blood cells</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in White Blood Cells at Month 1</title>
          <description>Laboratory hematology white blood cells</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 1.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="2.07"/>
                    <measurement group_id="O2" value="0.26" spread="2.04"/>
                    <measurement group_id="O3" value="-0.10" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in White Blood Cells at Month 3</title>
        <description>Laboratpry hematology white blood cells</description>
        <time_frame>Baseline, month 3</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in White Blood Cells at Month 3</title>
          <description>Laboratpry hematology white blood cells</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 3.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="1.93"/>
                    <measurement group_id="O2" value="0.40" spread="1.71"/>
                    <measurement group_id="O3" value="-0.05" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in White Blood Cells at Month 6</title>
        <description>Laboratory hematology white blood cells</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in White Blood Cells at Month 6</title>
          <description>Laboratory hematology white blood cells</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 6.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="1.78"/>
                    <measurement group_id="O2" value="0.04" spread="1.85"/>
                    <measurement group_id="O3" value="0.35" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in White Blood Cells at Month 12</title>
        <description>Laboratory hematology white blood cells</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in White Blood Cells at Month 12</title>
          <description>Laboratory hematology white blood cells</description>
          <population>Subjects who received at least 1 dose of investigational product who had nonmissing data at baseline and month 12.</population>
          <units>* 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="2.40"/>
                    <measurement group_id="O2" value="0.11" spread="1.86"/>
                    <measurement group_id="O3" value="0.13" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Common Terminology Criteria for Adverse Events (CTCAE) Grade Greater or Equal to 3</title>
        <description>Participants with laboratory toxicity of grade 3 or 4, graded according to the Common Terminology Criteria for Adverse Events, version 3.0, on the following general guideline:
Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death related to AE.</description>
        <time_frame>Month 1, month 3, month 6, month 12</time_frame>
        <population>Patients who received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 180 mg</title>
            <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg</title>
            <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Common Terminology Criteria for Adverse Events (CTCAE) Grade Greater or Equal to 3</title>
          <description>Participants with laboratory toxicity of grade 3 or 4, graded according to the Common Terminology Criteria for Adverse Events, version 3.0, on the following general guideline:
Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death related to AE.</description>
          <population>Patients who received at least 1 dose of investigational product.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine Amino Transferase-above normal (grade 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase-above normal (grade 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose-above normal (grade 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes-below normal (grade 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium-below normal (grade 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells-below normal (grade 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo subcutaneous injections on Day 1 and at Month 6.</description>
        </group>
        <group group_id="E2">
          <title>Denosumab 60 mg</title>
          <description>Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
        </group>
        <group group_id="E3">
          <title>Denosumab 180 mg</title>
          <description>Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

